论文部分内容阅读
1978年首次提出 ARDS 以来,已积累了大量有关其发病机理和治疗的资料。但至今其病死率仍高达60%,与20年前相同。疗效不佳的主因是尚无解决本病关键问题的疗法,无法打破疾病发展中的恶性循环。表面活性物质替代疗法,是目前治疗新生儿呼吸窘迫综合征(NRDS)的全新疗法,可达到即刻缓解,从而终止病情的进一步恶化。表面活性物质替代疗法可预防性地防止 NRDS,该法在危重病例抢救中也有一定价值。由于 NRDS 与 ARDS 有相似的病理生理过程,有理由认为表面活性物质替代疗法,将成为治疗成人肺疾病的有效手段。
Since ARDS was first proposed in 1978, a great deal of information has been accumulated about its pathogenesis and treatment. However, its case fatality rate is still as high as 60% so far, the same as it was 20 years ago. The main reason for poor efficacy is the lack of treatment for the key problems of this disease, can not break the vicious cycle of disease development. Surfactant replacement therapy is a brand new therapy currently available for the treatment of neonatal respiratory distress syndrome (NRDS), which delivers immediate relief, ending the progression of the condition. Surfactant replacement therapy can prevent NRDS prophylactically, which is of value in the rescue of critically ill patients. Because NRDS and ARDS have similar pathophysiological processes, it is reasonable to assume that surfactant replacement therapy will be an effective treatment for adult lung diseases.